AGPS and Alzheimer disease: An increase in β-amyloid (Aβ) levels associated with Alzheimer’s disease leads to oxidative stress in the brain and loss of peroxisomal function, while it also decreases the activity of alkylglycerone phosphate synthase (AGPS is the rate-limiting enzyme of ether lipid synthesis) and ultimately reduces the plasmalogen levels [27].